Monograph Wealth Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Monograph Wealth Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-8,850	Closed	-$480K	–	120
2024 Q1	$480K	Buy	+8,850	New	+$451K	0.07%	102
2023 Q4	–	Sell	-53,130	Closed	-$3.08M	–	112
2023 Q3	$3.08M	Buy	+53,130	New	+$3.26M	0.61%	21

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Monograph Wealth Advisors's BMY Position: Q2 2024 in Review

Monograph Wealth Advisors sold out of Bristol-Myers Squibb (BMY) in Q2 2024, closing a stake of 8,850 shares — an estimated $480K sold.

Monograph Wealth Advisors first reported a position in BMY in Q3 2023 and held it in 2 quarters. The position peaked at $3.08M in Q3 2023. 2,152 funds tracked by Wall St. Rank hold BMY as of Q2 2024.

Monograph Wealth Advisors reported no remaining Bristol-Myers Squibb position as of Q2 2024 after selling out during the quarter.
Monograph Wealth Advisors sold 8,850 Bristol-Myers Squibb shares in Q2 2024, an estimated $480K.
Monograph Wealth Advisors first reported a position in Bristol-Myers Squibb in Q3 2023 and held it in 2 quarters.
Monograph Wealth Advisors's Bristol-Myers Squibb position peaked at $3.08M in Q3 2023.
2,152 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2024.

Based on Monograph Wealth Advisors's 13F filing for Q2 2024, filed 15 Aug 2024.